• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection

tetano

Editor, Senior Moderator
J Med Virol


. 2021 Feb 21.
doi: 10.1002/jmv.26896. Online ahead of print.
High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection


L Courtellemont[SUP] 1 [/SUP], J Guinard[SUP] 1 [/SUP], C Guillaume[SUP] 1 [/SUP], S Giach?[SUP] 2 [/SUP], V Rzepecki[SUP] 2 [/SUP], A Seve[SUP] 2 [/SUP], C Gubavu[SUP] 2 [/SUP], K Baud[SUP] 2 [/SUP], C Le Helloco[SUP] 2 [/SUP], G N Cassuto[SUP] 3 [/SUP], G Pialoux[SUP] 4 [/SUP], L Hocqueloux[SUP] 2 [/SUP], T Prazuck[SUP] 2 [/SUP]



Affiliations

Abstract

Introduction: The SARS-CoV-2 pandemic has become a major public health issue worldwide. Developing and evaluating rapid and easy-to-perform diagnostic tests is a high priority. The current study was designed to assess the diagnostic performance of an antigen-based rapid detection test (COVID-VIRO?) in a real-life setting.
Methods: Two nasopharyngeal specimens of symptomatic or asymptomatic adult patients hospitalized in the Infectious Diseases Department or voluntarily accessing the COVID-19 Screening Department of the Regional Hospital of Orl?ans, France, were concurrently collected. The diagnostic specificity and sensitivity of COVID VIRO? results were compared to those of real-time reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) results. A subset of patients underwent an additional oropharyngeal and/or saliva swab for rapid testing.
Results: A total of 121 patients confirmed to be infected and 127 patients having no evidence of recent or ongoing infection were enrolled for a total of 248 nasopharyngeal swab specimens. Overall, the COVID-VIRO? sensitivity was 96.7% (IC: 93.5%-99.9%). In asymptomatic patients, symptomatic patients having symptoms for more than 4 days and those with an RT-qPCR cycle threshold value ≥32, the sensitivities were 100%, 95.8% and 91.9%, respectively. The concordance between RT-qPCR and COVID VIRO? rapid test results was 100% for the 127 patients with no SARS-CoV-2 infection.
Conclusion: The COVID-VIRO? test had 100% specificity and a sensitivity greater than 95%, which are better than the recommendations set forth by the WHO (specificity ≥97-100%, sensitivity ≥80%). These rapid tests may be particularly useful for large-scale screening in emergency departments, low-resource settings and airports. This article is protected by copyright. All rights reserved.

Keywords: Chromatographic techniques < Research and Analysis Methods; Local infection/Replication/Spread < Pathogenesis; SARS coronavirus < Virus classification.
 
Back
Top Bottom